MedTrace Logo

Study of VX-985 in Subjects With Chronic Hepatitis C

NCT01144936 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2011-03-09

No results posted yet for this study

Summary

The purpose of this study it to evaluate the safety and tolerability of VX-985 in HCV subjects. This study will also evaluate the antiviral activity and pharmacokinetic profile of VX-985.

Conditions

  • Chronic Hepatitis C

Interventions

DRUG

VX-985 or matching placebo

low dose

DRUG

VX-985 or matching placebo

high dose

DRUG

VX-985 or matching placebo

dose TBD

Sponsors & Collaborators

Principal Investigators

  • Lisa Mahnke, MD, PhD · Vertex Pharmaceuticals Incorporated

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2010-10-31
Completion
2010-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01144936 on ClinicalTrials.gov